Clinical trial

Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib

NCT07237256

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2025-12-18

PhasePHASE3

Study timeline

Study start (actual)2025-12-18Date precision: day

Registry last updated2026-05-26

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

Interventions

Chemotherapy followed by endocrine therapy and ribociclib treatmentDRUG

De-escalationOTHER

Sponsors & collaborators

UNICANCERlead sponsor

Novartiscollaborator

SOLTI Breast Cancer Research Groupcollaborator

GBG Forschungs GmbHcollaborator

Latin American Cooperative Oncology Groupcollaborator

Gruppo Italiano Mammella (GIM)collaborator

BOOG Study Centercollaborator

Canadian Cancer Trials Groupcollaborator

Swiss Cancer Institutecollaborator

Menarini Silicon Biosystems, INCcollaborator

Mapped research locations

BarcelonaSpain3 ParisFrance3 BerlinGermany2 LyonFrance2 BordeauxFrance2 NaplesItaly2 MünsterGermany2 DüsseldorfGermany2 LimogesFrance2 MadridSpain1 HamburgGermany1 ValenciaSpain1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07237256 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.